This inventor holds 3 USPTO granted patents and 4 published patent applications and 1 EPO patent. Top assignees: Novelty Nobility Inc., Genesen Co., Ltd.. Active years: 2019-2024.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2019-2024
Title: Tae Hyeon Yoo: Innovator in Antibody Conjugation Technology
Introduction
Tae Hyeon Yoo is a prominent inventor based in Yongin-si, South Korea. He has made significant contributions to the field of biotechnology, particularly in the area of antibody conjugation. With a total of 3 patents to his name, Yoo's work is paving the way for advancements in drug development.
Latest Patents
Yoo's latest patents focus on methods for conjugating antibodies with physiologically active substances. One of his notable inventions includes an antibody conjugating peptide that features an amino acid with a photoreactive functional group. This innovative approach allows for a physiologically active substance to be modified with the conjugating peptide. The resulting antibody conjugate demonstrates improved conjugation efficiency compared to conventional methods. This advancement ensures that the drug can be firmly bound without compromising the specificity of the antibody, thereby facilitating the commercialization of antibody conjugates.
Career Highlights
Throughout his career, Tae Hyeon Yoo has worked with several companies, including Novelty Nobility Inc. and Genesen Co., Ltd. His experience in these organizations has contributed to his expertise in the field of biotechnology and patent development.
Collaborations
Yoo has collaborated with talented individuals such as Jisoo Park and Yumi Lee. These partnerships have further enhanced his research and development efforts in antibody conjugation technology.
Conclusion
Tae Hyeon Yoo is a distinguished inventor whose work in antibody conjugation is making a significant impact in the biotechnology sector. His innovative patents and collaborations are essential for advancing drug development and commercialization.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile